ID	DDInter2140
	Drug Type	biotech
	Protein Chemical Formula	C6400H9844N1732O1992S52
	Protein Average Weight	147000.000
	CAS Number	1572943-04-4
	Description	Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling.[A243764, A243769] Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes. Blocking the interaction of TSLP with the receptors TSLPR and IL-7Rα improves asthma-associated biomarkers including eosinophil counts and IgE, FeNO, IL-5, and IL-13 levels.[A243764, A243769, A243774] As existing asthma treatments such as [omalizumab], [mepolizumab], [reslizumab], [benralizumab], and [dupilumab] act on specific downstream mediators of the inflammatory response, they are mostly limited to treating T2 asthma.[A243769] Conversely, tezepelumab, which targets the upstream master regulator TSLP, has the potential to be effective across asthma endotypes.[A243764, A243769, A243774] Tezepelumab is a human monoclonal IgG2λ antibody directed against TSLP produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.[L39504]
	ATC Classification	R03DX11
Sequences	None
Useful Links	DrugBank Wikipedia